NewsBenzingaRBC Capital mantiene su recomendación de sobreponderar a Corbus Pharmaceuticals y reduce el precio objetivo a 33 dólares RBC Capital mantiene su recomendación de sobreponderar a Corbus Pharmaceuticals y reduce el precio objetivo a 33 dólares Benzinga 2026.11.11 15:18 (GMT+0) Open on Benzinga Other news Musk: Expects SpaceX to sell no compute to OpenAI Wall Street prepares for Anthropic IPO frenzy, despite broader AI stock slump Iron Mountain Stock: Is Wall Street Bullish or Bearish? HTX DeepThink: Leverage Flush-Out May Not Mark a Bottom; Weak Spot Demand Could Keep BTC Under Pressure What Wall Street analysts are now saying after Nvidia’s beat-and-raise quarter More Than a Swap: PancakeSwap Rebrands as Pancake Ahead of Mobile App Launch
HTX DeepThink: Leverage Flush-Out May Not Mark a Bottom; Weak Spot Demand Could Keep BTC Under Pressure